HawkCell’s Post

Join us at Booth #102 at EMIM in Porto, Portugal! 🌍✨ Explore the latest innovations in preclinical imaging and connect with industry experts! See you there! #EMIM2024 #Booth102 #Porto #Innovation"

I am so excited to learning more about these technologies!

𝐑𝐞𝐯𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐢𝐳𝐢𝐧𝐠 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐚𝐧𝐝 𝐏𝐚𝐭𝐢𝐞𝐧𝐭 𝐒𝐚𝐟𝐞𝐭𝐲: 𝐓𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦𝐢𝐧𝐠 𝐒𝐜𝐢𝐞𝐧𝐜𝐞 𝐅𝐢𝐜𝐭𝐢𝐨𝐧 𝐢𝐧𝐭𝐨 𝐑𝐞𝐚𝐥𝐢𝐭𝐲 On 07th May, the IVAM Microtechnology Network will present technologies that have transitioned from fantasies in science fiction movies to actual technological reality. Which technologies were imagined or depicted in films several years or decades ago? What was once pure technological fantasy in the past and is reality today? I am honored to chair the extraordinary session on “Innovative Visions - Advancing Medtech for the Next Era”, highlighting our unwavering dedication to revolutionize vascular access and transform patient safety, bringing it to our daily reality at Ebnet Medical. I invite you to join me, along with a remarkable lineup of medtech innovators, such as Dr. Ulisses Jesús Gutiérrez Hernández from FlowBeams and the University of Twente, presenting the development of a needle-free injection technology. Additionally, Eilien Heinrich from Fraunhofer IMM and Nicolas Schierbaum from Fraunhofer-Institute for Microelectronic Circuits and Systems will talk about advanced microtechnologies for single cell analysis in RNA-based cell and gene therapies. Lastly, Dr. Jochen Hoffmann from Bosch Research will present the decentralized molecular diagnostics platform Vivalytic. Let's innovate, collaborate, and revolutionize healthcare and patient safety together. Empathy and practical experience are key! https://lnkd.in/eEkVBvnW #vascularaccess #infusiontherapy #innovation #patientcare #patientsafety #medtech #event

"Excited to share that I've recently completed a research project as a part of ReachSci Hackathon, focused on evaluating the feasibility and cost-effectiveness of phone-linked biosensors for detecting MicroRNA 184 in the saliva of OSCC patients. In just 7 days, we explored MicroRNA 184 as a potential diagnostic biomarker and investigated the development of a graphene oxide-based biosensor for its detection in OSCC. #ReachSciHackathon #Research #Biosensors #OSCCDetection #Innovation"

Last week Nicholas Akosa attended the AMC meeting in Birmingham The AMC or ATMP manufacturing community brings together stakeholders from across the #CellandGeneTherapy ecosystem with a shared focus on manufacturing. Last weeks' event - it's 25th! - was a deep dive into the evolving landscape of autologous cell therapies and their manufacturing processes. Here are some of our key takeaways: 👉 Technology Transfer in Autologous Processes: Holly Garlick highlighted the importance of considering variability in patient material and the strategies to manage it. These included really defining patient starting material, conducting runs where variability is introduced into starting material to determine potential impact, and implementing split batches to assess manufacturing consistency across different sites. 👉 Decentralised Manufacturing Networks: adthera bio’s Stuart Curbishley discussed how decentralised manufacturing not only brings flexibility but also positions production closer to patients, and how important the integration of analytics into bioreactors is for optimising manufacturing processes. 👉 Challenges in Clinical Delivery: The talk led by Paul Ferguson and Francesca Kinsella shed light on the critical need for increasing manufacturing capacity. Their insights into the limitations faced by current facilities emphasise the urgency to expand cleanroom capabilities to meet patient needs, especially as new cell therapies are developed for indications with larger patient populations. 👉 Innovations in Digital and Machine Learning Applications: The panel featuring Stephen Goldrick, Marc-Olivier Baradez, Andrew Craig, and Kwok Pang highlighted the lack of digital readiness of current manufacturing platforms. The talk highlighted many benefits of digitisation and digital twins in manufacturing processes, and also delved into some of the current challenges that are being overcome, which will facilitate manufacturing processes becoming more digitised. The day was a fantastic opportunity to network with pioneers and gather insights that reinforce the importance of innovation and adaptability in the field of cell therapy. We’re looking forward to applying these insights to our projects and pushing the boundaries of what we can achieve in biotechnology! #AMC2024 #CellTherapy #Biotechnology #Innovation #MFX

At Eve Technologies, we're proud to leverage the cutting-edge Multiplexing LASER Bead Technology to transform biomedical testing. This advanced technology, recognized with the Frost & Sullivan Technology Innovation Award, enables the simultaneous detection of up to 100 different analytes in a single well. Why It Matters: ✔ High Efficiency: Perform up to 100 assays simultaneously on a single sample. ✔ Cost-Effective: More affordable and efficient than traditional methods like ELISA. ✔ Low Sample Volume: Requires only 2-25 µl of sample, reducing waste and improving sustainability. From cytokine arrays to cancer marker detection, our multiplex technology supports a wide range of applications, making it a powerful tool for modern research. Explore how our technology can advance your research. #BiomedicalResearch #MultiplexTechnology #LabServices #CytokineAnalysis #ResearchInnovation #EveTechnologies

🔍 Wondering why preclinical imaging should be on your radar? This video breaks it down for you!   • Invaluable Insights: Preclinical imaging supports many research fields by providing new and integrated in vivo insights. • Non-invasive and longitudinal monitoring: Fully compliant with the 3Rs principles, allowing researchers to study disease in real-time quantitatively at a molecular level. • Monitor Progress: Repeatedly and non-invasively monitor disease onset, progression, and treatment response.   With the CUBES, you can benefit from scalable, compact, and intuitive imaging solutions with the highest performance supported by fast and simple workflows. Our state-of-the-art modular benchtop solutions make molecular imaging more accessible to a broader community of researchers in preclinical drug discovery, development, and fundamental and translational research.   👉 Ready to elevate your research game? Visit our website to learn more! Or visit us at #EANM24 in Hamburg from 19 until 23 October, Hall H booth H10.   #MolecularImaging #PreclinicalImaging #PreclinicalResearch

Mark Anderson will be presenting on the Biotech Showcase Stage, located in Room 303, on Wednesday, September 11 @ 4:15PM. We invite you to attend and would be happy to schedule time before or after the presentation to meet and discuss Pattern in further detail. Pattern is a pioneer in finding novel patterns in complex data that cannot be discovered using other techniques or tools. The speed of AI innovation is accelerating and is rapidly emerging as a strategic imperative. Pattern is optimally positioned to leverage the expertise of our Pattern Discovery Engine™ (PDE) into the next worlds of trustworthy, transparent computing. Since its founding, Pattern has been on a strategic path with a roadmap largely focused on building our PDE and using it to generate high-value assets, which we are now at an inflection point to commercialize. These assets include and are not limited to: combination cancer drug discoveries and diagnostic advances against the world’s top five cancers, in which we are looking to partner with firms to bring these drugs into clinical trials; the Pattern Discovery Engine™; ProSpectral™, a game-changing medical diagnostic tool and research instrument; and TrueXAI™. These products have already led to major new pattern discoveries in the most competitive and important fields of endeavor. With continued innovation and collaboration, we can create a better future for everyone. LSX - partnering for Life Science eXecutives #biotech #drugdiscovery #advancedcomputing #innovation

🎖️Check out the Editor's Choice #Review "Antibody–Drug Conjugates: The Dynamic Evolution from Conventional to Next-Generation Constructs" 👥by Virginia Metrangolo and Lars Engelholm Biotech Research & Innovation Centre (BRIC), University of Copenhagen Københavns Universitet - University of Copenhagen 🔗Link here: https://lnkd.in/evG8Bdif 🔶Antibody–drug conjugates (ADC) are targeted oncotherapeutics with the validated potential to create significant clinical impact. This comprehensive review covers the recent evolution of ADC design and development discussing molecular challenges and opportunities for further improvements.🔶

I hope you can join the team at #IndicaLabs for this informative webinar on highly multiplexed IF workflows with HALO, presented by Dr. Anne Hellebust, Director of Product, Life Sciences. Register today for the event on the 25th. I hope to see you there! #digitalpathology